prove lethal for approximately 27,000 men this year (1) , it is estimated that almost half of men diagnosed by prostate-specific antigen (PSA) screening will develop a form of disease that is not life threatening and will likely remain indolent over the course of a lifetime (2) . As a result, thousands of men needlessly undergo radical treatment for CaP each year and are exposed unnecessarily to substantial morbidity. Yet, treatment for the substantial minority with deadly forms of disease is vitally important. Accurate prognostication regarding prostate cancer aggressiveness is therefore critical for patients and their physicians.
Widely accepted prognostic factors include stage of disease, tumor differentiation (Gleason sum), and PSA. These three parameters also have been combined for prediction of recurrence after local treatment (3) . However, each of these clinical predictors has significant shortcomings. For example, biopsy Gleason sum, the factor most strongly associated with outcome, is inherently subject to selective sampling of tumor, which is not often not representative of the overall tumor(s). Even when sampling error is not an issue, heterogeneity in outcome is well described, and high Gleason score (>7), for example, has a positive predictive value for mortality of only 29% (4) . Improved predictors of long-term outcome, available at the time of diagnosis, are needed. associated with risk, it is less clear whether the SNPs are also associated with clinical variables that help predict outcome. The discovery of germline risk polymorphisms provides an opportunity to determine the effects of these variants on clinically relevant issues related to CaP. Previous studies have demonstrated a modest association between certain risk alleles and parameters such as Gleason score, age at diagnosis, or disease aggressiveness (17) (18) (19) , whereas other studies have not detected these associations. Most of these studies focused solely on clinical surrogates for outcome. Few studies have evaluated associations between risk allele status and CaP-specific mortality (20) (21) (22) (23) , and no study has evaluated all of the known risk loci to date for CaP-related death
In the present study, 3,945 prostate cancer patients were genotyped for 35 SNPs associated with CaP risk. We also genotyped one SNP which recently was reported to be associated specifically with aggressive disease (24) . We assessed associations between genotype and CaP-specific survival to determine whether previously identified risk SNPs can differentiate men who develop low-risk, indolent forms of the disease from men who develop lethal prostate cancer.
METHODS

Study population
The Gelb Center prostate cancer cohort at Dana-Farber Cancer Institute has been described previously (25) and includes blood samples from over 6,000 patients followed prospectively. Clinical data are collected from multiple sources, including medical records, institutional laboratory, patient registration, pharmacy systems, and clinician forms. Men included in the study had a known date of diagnosis and information available regarding PSA at diagnosis, biopsy Gleason score and clinical stage at diagnosis. Each subject consented for clinical data and provided a blood samples for DNA extraction for research use. Only European American subjects were included in the study, and the majority provided reliable ancestry data. Ancestry information was confirmed for a subset of patients and determined for all subjects without self-reported data by genotyping 26 ancestry-informative SNPs (26) . A total of 3,945 were included in the study.
Age at diagnosis was considered age at the date of first CaP-positive biopsy. PSA at diagnosis was the last PSA value within three months prior to diagnostic biopsy. Gleason score used in the study was based on prostate biopsy. All biopsy samples were reviewed by pathologists at Brigham and Women's Hospital. D'Amico criteria were used to classify aggressiveness of patients' disease at diagnosis as having low, intermediate or high risk disease (27) . The criteria were developed to classify men with localized disease. Since men with metastases at presentation were included in the present study, the criteria were modified to include this subset. Groups were defined as low-risk (PSA <10 ng/mL, Gleason score <6, and clinical stage T1c or T2a), intermediate-risk (PSA 10-20 ng/mL or Gleason 7 disease or clinical stage T2b, and otherwise low-risk features), and high-risk (PSA >20 or Gleason >8 or stage T2c-M1). Aggressiveness based on these criteria was able to be defined for a total of 3500 patients. CaP-specific mortality was considered any death in the setting of castration-resistant CaP and CaP metastases. Records of over 300 patients who died and did not meet these criteria were reviewed by an oncologist (M.P.) to determine cause of death and establish that CaP was not the immediate cause.
SNP selection
Thirty-five SNPs chosen for analysis met genome-wide statistical significance for association with prostate cancer risk in multi-stage GWAS analyzing more than one independent cohort of cases and controls published between 2006 and 2009 (5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . If two risk SNPs discovered at the same locus were in linkage disequilibrium r2>0.50, only one was included in the present study. In addition, one SNP, rs4054823, recently reported to be associated with aggressive disease was included in the analysis (24) .
DNA extraction and genotyping
All DNA samples were extracted from peripheral whole blood using QIAamp DNABlood mini kit (QIAGEN Inc, Valencia, CA). Genotyping was carried out using Sequenom iPLEX matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology (Carlsbad, CA). All risk SNP assays were combined into four multiplex pools. All reactions were carried out in 384-well format. Approximately 5% of samples were randomly selected and genotyping duplicated for quality control.
Concordance rate for duplicate genotyping was 100%. Call rate overall was greater than 99%.
Statistical method
Cancer Research. The method of Kaplan Meier was used to estimate survival distribution. CaP-specific survival was defined from prostate cancer diagnosis to time of death, which was related to prostate cancer or censored on the last known alive date, or death of other causes.
Hazard ratios (HR) and associated 95% confidence intervals (CI) for prostate cancer specific survival among different genotypes were calculated in univariate analysis as well as adjusting for clinical characteristics at diagnosis, using a Cox proportional hazard model for cause-specific hazard. Competing risk for other causes of death were assessed as a sensitivity analysis.
The study had over 80% power to detect a range of HR between 1.5-1. 
RESULTS
The study cohort consisted of 3,945 prostate cancer patients of European ancestry.
Characteristics of the study subjects are summarized in Table 1 There were 580 prostate cancer-specific deaths, defined as death in the setting of metastatic, castration-refractory disease, accounting for 66% of all deaths (N=883). A total of 36 SNPs (35 risk SNPs and one SNP reported to be associated with aggressiveness) were chosen for analysis as described in Methods and listed in Table 2 .
Risk allele frequencies are similar to those detected in CaP cases from previous GWAS conducted in men of European ancestry.
Each SNP was initially analyzed using a multiplicative model for association between genotype and the following clinical variables at the time of diagnosis: age, PSA, biopsy
Gleason score, and aggressiveness groups based on D'Amico criteria (27) . In addition, each SNP was analyzed for association with CaP-specific survival. Twelve SNPs achieved a p-value <0.05 for association with at least one clinical variable analyzed (Table 3 The SNP rs2735839 at chromosome 19q13 was significantly associated with CaPspecific mortality ( Figure 1A , Table 4 ). The protective (non-risk) allele (A) was associated with increased risk of dying of the disease (p=7x10 -4 ). The unadjusted hazard ratio (HR) for CaP-specific death among patients carrying one A allele, i.e. heterozygous for the SNP, was 1.26 (95% CI, 1.05-1.52) when compared with homozygotes for the risk allele (GG). For AA homozygotes, the HR was 2.14 (95% CI, 1.33-3.44). The non-risk allele at rs2735839 was also associated with earlier onset of disease, higher Gleason score and higher risk disease (Table 3) . Risk allele status at rs2735839 was not associated with PSA level at diagnosis. When adjusting for PSA level, the association with prostate cancer-specific survival was still present (p=0.03), though the association was no longer present when adjusting for Gleason score (p=0.1). After adjusting for aggressiveness according to D'Amico criteria and age at diagnosis, HRs for CaP-specific mortality was 1.23 (95% CI, 1.01-1.47) for heterozyotes (AG) and was 1.92 (95% CI, 1.20-3.09) for AA homozygotes when compared to homozygotes for the risk allele (GG) (p=0.005) (Table 4) .
Recent data implicate the risk variant at the chromosome 19q13 locus in the regulation of PSA level (10, (28) (29) (30) (31) (32) (33) (34) . In a cohort consisting of men diagnosed largely via PSA screening, an association with PSA level could lead to ascertainment bias when evaluating associations with outcome. To account for this possibility, prostate cancerspecific survival was analyzed in a subgroup of patients (n=237) diagnosed prior to 1993, the beginning of the PSA era. It is presumed that few in this subgroup underwent PSA screening. With 50% power to detect a HR of 2.0, no association with mortality was 
observed: HR for the AG genotype was 1.13 when compared with the GG genotype (pvalue= 0.56).
The SNP rs7679673 at chromosome 4q24 was also associated with prostate cancerrelated death ( Figure 1B , Table 4 ). The risk allele (C) was associated with an increased hazard of dying of CaP (p=0.014). Compared with men carrying the non-risk AA genotype, the unadjusted HR for men heterozyogous for this SNP was 1.22 (95% CI, 0.95-1.57) and was 1.44 (95% CI, 1.11-1.86) for men homozygous for the risk allele (C).
After adjusting for aggressiveness and age at diagnosis the association remained significant (P=0.002). The adjusted HR for CC was 1.56 (95% CI, 1.20-2.02) and 1.27 (95% CI, 1.00-1.63) for AC when compared to homozygote AA (Table 4 ). The rs7679673 risk SNP was also associated with earlier onset of disease (p=0.0013).
The cumulative incidence method for competing risk of death from other causes was also performed. The cumulative incidence of an event of interest (CaP-specific mortality) was calculated in the presence of competing risks (death from other causes). For both rs2735839 and rs7679673, the direction, magnitude and significance of effects on CaPspecific survival were consistent with the results described above (data not shown). 
defined three different ways in the populations analyzed. As in the present study, criteria for aggressiveness were based on Gleason score, stage and PSA. When the definition for aggressiveness used by Xu et al in their discovery set was applied to our cohort, no association was observed with genotype at rs4054823 (data not shown).
The model for best evaluating the relationship between risk allele status and clinical outcome is not known. While meaningful associations between genotype at independent risk SNPs and clinical phenotype may exist, the number of risk alleles an individual carries may influence disease aggressiveness. To evaluate this hypothesis, subjects were categorized based on total risk allele burden. An individual can carry a total of 70 risk alleles (35 risk SNPs x2 alleles per SNP). Subjects in the present cohort carried a median 32 risk alleles (range, 11-47). The cohort was split into quartiles based on risk allele status and associations with age at diagnosis, PSA at diagnosis, biopsy Gleason score, D'Amico criteria, and CaP-specific mortality were analyzed. An association with age at diagnosis was detected (p=4x10 -5 ); the difference in median age between those carrying the fewest risk alleles (<29) and those carrying the most (>35) was two years (median 62 years versus 60 years, respectively). No statistically significant trends were observed for CaP-specific mortality or the other clinical parameters evaluated. SNPs and clinical outcome (22, 23, 29) . The cohort includes 580 CaP-specific deaths, making this the largest study of its kind to evaluate this critical outcome. With 3,945 individuals and a 15% event rate, we have 80% power to detect a HR ranges from 1.5-1.7 for the risk allele frequency varying from 0.10 -0.25. We detected two alleles that were significantly associated with CaP-specific mortality: the rs2735839 non-risk allele (A) (p=0.0007) and the rs7679673 risk allele (C) (p=0.014). KLK3 (also known as kallikrein 3) encodes PSA, and KLK2 encodes kallikrein-related peptidase 2 (hK2), which, like PSA, is a known biomarker for CaP. Variation at this locus has been associated with PSA levels in men in several, though not all, studies (10, (28) (29) (30) (31) (32) (33) 36) , and these changes have been observed primarily in subjects without a diagnosis of CaP. Recently, Gudmundsson et al scanned the entire genome for genetic variants associated with PSA level. Notably, the risk allele at rs2735839 was highly associated with this phenotype in men not diagnosed with prostate cancer (34 Given that carriers of the risk allele have a naturally higher PSA, there has been debate regarding whether its association with disease risk is authentic or the product of ascertainment bias due to its association with PSA. It has been reasoned that when men are screened for CaP, carriers of the "risk" allele are more likely to meet a clinician's threshold for prostate biopsy compared with a non-carrier with similar underlying tumor biology. This results in increased incidence of CaP among carriers. Counterparts carrying the non-risk allele have a lower PSA and presumably a decreased likelihood of receiving a CaP diagnosis. This was reflected in Eeles et al, the first GWAS describing rs2735839 as a risk locus (10) . Stage 1 of that analysis used a control group selected based on low PSA. The minor allele frequency of rs2735839 in the control group in stage 1 was appreciably higher than the minor allele frequency in stage 2 where stringent PSA criteria were not used. In their GWAS analyzing PSA levels, Gudmundsson et al observed an association between variation at 19q13 and prostate cancer risk, but only for those diagnosed in the PSA screening era (34).
On the other hand, in the GWAS by Eeles et al the association between rs2735839 persisted, albeit at a markedly lower significance level, in non-PSA screened cohorts (29) . In addition, functional data have implicated genetic variation at KLK3 in increased risk of cancer development, consistent with the possibility that the locus is associated with both PSA and disease risk (31) . On the other hand, other aspects of the present study are consistent with a true association between the protective allele and lethal disease. First, no association between rs2735839 genotype and PSA was observed, albeit in a cohort of CaP cases. Second, the association with CaP-specific mortality was maintained in multivariable analysis that included age at (38) . No other study, to our knowledge, has evaluated rs7679673 locus for its association with CaP-specific survival.
For the variables age at diagnosis, PSA at diagnosis, Gleason score, and aggressiveness, there was no marked overlap between the findings presented here and data previously published. Two chromosome 17 risk SNPs (rs4430796 and rs1859962) were associated with early onset of disease on univariate analysis here (p<0.05), an association also reported by Gudmundsson et al. that did not reach statistical significance (7) . Two groups reported that the rs10993994 risk allele at chromosome 10q was associated with less aggressive disease (19, 28) , an association not observed here. identify a SNP, rs4054823, associated with aggressive CaP (24) . In our cohort, this SNP was not associated with aggressive disease (p=0.697) or CaP-specific mortality (p=0.12).
We also attempted to evaluate total number of risk alleles carried by an individual and its associations with clinical presentation and outcome. While it is possible that several inherited risk variants from various loci contribute collectively to the development particular phenotype, it is unclear how best to model this. We chose to add the number of risk alleles to quantify an individual's "risk allele burden." Those carrying a greater number of risk variants were diagnosed at an earlier age than those carrying fewer risk variants (p=4x10 -5 ). No other clinical parameter was associated with overall risk allele status. However, it is difficult to determine how best to integrate all of the genetic data.
In some cases, as with rs2735839, a non-risk allele may be associated with a more aggressive phenotype, and in other cases the risk allele may be associated with more aggressive disease.
Genome-wide scans have successfully identified inherited variants associated with CaP risk. In order to fully utilize these markers in clinic, it is critical to fully understand the clinical implications of carrying the risk alleles, particularly their impact on mortality.
Our study identifies two SNPs associated with CaP-specific disease. Further work is necessary to characterize these risk loci and determine how to optimally translate these findings into clinical practice. 
